Five year summary 12 months to 12 months to 12 months to 12 months to 12 months to 31 Dec 1998 31 Dec 1999 31 Dec 2000 31 Dec 2001 31 Dec 2002 restated restated restated restated m m m m m Key data Sales 1,388.9 1,374.6 1,377.6 1,602.5 1,618.2 continuing operations 1,113.7 1,271.0 1,377.6 1,602.5 1,618.2 discontinued operations 275.2 103.6 Amersham Health 161.0 178.1 194.6 240.9 255.6 Amersham Biosciences 70.5 81.6 63.3 72.4 75.3 Corporate 9.9 9.7 16.7 20.8 21.1 Operating profit of continuing operations before exceptional items and goodwill amortisation 221.6 250.0 241.2 292.5 309.8 Discontinued operations 37.7 10.3 Total operating profit before exceptional items and goodwill amortisation 259.3 260.3 241.2 292.5 309.8 Interest 33.3 27.1 10.0 8.7 7.1 Amounts written off investments 4.4 2.4 profit before tax and before exceptional items and goodwill amortisation 226.0 233.2 231.2 279.4 300.3 Exceptional items 35.1 55.2 27.0 46.6 Goodwill amortisation 2.4 8.9 10.7 11.7 36.6 profit before taxation after exceptional items and goodwill amortisation 188.5 169.1 193.5 314.3 263.7 profit attributable to shareholders 99.4 87.9 107.0 210.7 178.7 Employment of shareholders funds Fixed assets 751.2 677.5 776.7 787.9 1,491.4 Net current assets 398.4 360.0 266.2 269.8 146.5 Non-current liabilities incl.
Sales have been restated to reclassify Industrial Quality & Safety Assurance and Nycomed Pharma as discontinued operations.
Figures for periods ending 31 December 1998, 1999 and 2000 have been restated following the introduction of FRS18.
Figures for periods ending 31 December 1998, 1999, 2000 and 2001 have been restated following the introduction of FRS19, as explained in note 36 to the financial statements.
92 Amersham plc Annual Report & Accounts 2002
